Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 5/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15061554 | 1.00 | LMNA (0.45) | LMNACCR5TAAR1CYP2D6MEN1 | |
| Ammonia Solution, Strong SCHEMBL27550294 | 0.98 | LMNA (0.43) | LMNACCR5TAAR1CYP2D6MEN1 | |
| SCHEMBL3385362 | 0.88 | LMNA (0.42) | LMNACCR5TAAR1CYP2D6HRH1 | |
| SCHEMBL4354924 | 0.86 | HRH1 (0.42) | LMNATAAR1CYP2D6HRH1HTR2A | |
| SCHEMBL9869713 | 0.86 | SIGMAR1 (0.42) | LMNACCR5TAAR1CYP2D6HRH1 | |
| SCHEMBL3375650 | 0.85 | AOC3 (0.42) | LMNACCR5TAAR1HRH1HTR2A | |
| SCHEMBL11099949 | 0.84 | NR1I2 (0.44) | LMNACCR5TAAR1CYP2D6HRH1 | |
| SCHEMBL17183751 | 0.84 | NR1I2 (0.44) | LMNACCR5TAAR1CYP2D6HRH1 | |
| SCHEMBL27567790 | 0.84 | NR1I2 (0.44) | LMNACCR5TAAR1CYP2D6HRH1 | |
| SCHEMBL17183686 | 0.84 | NR1I2 (0.44) | LMNACCR5TAAR1CYP2D6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 517 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108211422-B | Device and method for reducing caprolactam in benzene extraction raffinate | 阳煤集团太原化工新材料有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-113710637-B | Preparation method of biaryl phosphine | 日本化学工业株式会社 | 2023-10-24 | — | — | CN | disclosed |
| WO-2023182221-A1 | METHOD FOR PRODUCING QUANTUM DOTS | 日本化学工業株式会社 | 2023-09-28 | — | — | WO | disclosed |
| CN-111655708-B | 2, 3-biphosphinopyrazine derivative, process for producing the same, complex compound, catalyst, and process for producing organoboron compound | 日本化学工业株式会社 | 2023-08-25 | — | — | CN | disclosed |
| US-11718758-B2 | Aqueous dispersion of colored particles | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2023-08-08 | — | — | US | disclosed |
| EP-3725854-B1 | COLORED PARTICLE AQUEOUS DISPERSION | MITSUBISHI PENCIL CO (JP) | 2023-07-05 | — | — | EP | disclosed |
| CN-111465662-B | Aqueous dispersion of coloured particles | 三菱铅笔株式会社 | 2023-05-26 | — | — | CN | disclosed |
| US-20230095021-A1 | MODULATORS OF TDP-43 | ALTERON THERAPEUTICS, LLC | 2023-03-30 | — | — | US | disclosed |
| CN-111032668-B | Optically active 2,3-bisphosphinylpyrazine derivative, process for producing the same, transition metal complex, and process for producing organoboron compound | 日本化学工业株式会社 | 2022-10-14 | — | — | CN | disclosed |
| US-20220177509-A1 | PRODUCTION OF BRIDGED ARTIFICIAL NUCLEOSIDES | NIPPON SHOKUBAI CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
| EP-0203722-A1 | Bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0203723-A1 | 2,3-(dihydro)bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0202794-A1 | 7-Substituted-2,3-(Dihydro) bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-26 | — | — | EP | disclosed |
| EP-0202047-A1 | Pyrazolidinium ylides | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
| EP-0202046-A1 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
| CN-86102877-A | The method for preparing bicyclic pyrazolidinones | — | 1986-10-29 | — | — | CN | disclosed |
| US-4517002-A | Phosphorodiamide urease inhibitors and urease inhibited urea based fertilizer compositions | ALLIED CORPORATION (US) | 1985-05-14 | — | — | US | disclosed |
| EP-0119494-A1 | Urease inhibited urea based fertilizer compositions containing phosphorus compounds | ALLIED CORPORATION (US) | 1984-09-26 | — | — | EP | disclosed |
| US-3957928-A | S-AMMONIUM-O-HYDROCARBYL-N-ACYL PHOSPHORAMIDOTHIOATE SALT PRODUCTION AND REACTION WITH ALKYLATING AGENT | CHEVRON RESEARCH COMPANY (US) | 1976-05-18 | — | — | US | disclosed |
| US-3931218-A | HYPOGLYCEMIC ANTIRESERPINE, ANTIULCER, OGENIC, ANTIARRHYTHMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230095021-A1 | MODULATORS OF TDP-43 | TARDBP, TDP1, TDP2 | LMNA 388/4885CCR5 4039/4885TAAR1 4086/4885 |
| US-20220177509-A1 | PRODUCTION OF BRIDGED ARTIFICIAL NUCLEOSIDES | TYMP, PNP, TYMS | LMNA 2504/4885CCR5 3222/4885TAAR1 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.